Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 7Phase 3 6Phase 1/2 5Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 1Advanced Neuroendocrine Neoplasm 1

Interventions

lutetium Lu 177 dotatate 2Fluorouracil 2Everolimus 2trametinib 1toripalimab 1fosbretabulin 1fluorocholine 1dabrafenib 1combretastatin 1cobimetinib 1anlotinib 1Water 1Vemurafenib 1Testosterone 1Temozolomide 1Somatostatin 1Sodium Iodide 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Radiofrequency Ablation 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1PE regimen 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Injections 1Erythromycin 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × lutetium Lu 177 dotatate × Endocrine × Clear all
NCT06398444 2025-09-05

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Sinotau Pharmaceutical Group

Phase 2/3 Active not recruiting
74 enrolled
Endocrine

Advanced Neuroendocrine Neoplasm

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed
26 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡